Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.52 |
| ▸ | VEGFA | P15692 | 4/20 | 0.47 |
| ▸ | FLT1 | P17948 | 4/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564198 | 1.00 | EGLN1 (0.52) | EGLN1VEGFAFLT1EGLN3MEN1 | |
| SCHEMBL1921757 | 0.90 | MAPT (0.45) | EGLN1MEN1KMT2AL3MBTL1SPHK2 | |
| SCHEMBL14150287 | 0.90 | KMT2A (0.48) | EGLN1MEN1KMT2AL3MBTL1 | |
| SCHEMBL15486308 | 0.89 | EGLN1 (0.59) | EGLN1EGLN3SPHK2P4HTM | |
| SCHEMBL23222953 | 0.87 | EGLN1 (0.51) | EGLN1VEGFAFLT1EGLN3MEN1 | |
| SCHEMBL1922771 | 0.87 | SPHK2 (0.59) | EGLN1MEN1KMT2AL3MBTL1SPHK2 | |
| SCHEMBL7909041 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2AL3MBTL1SPHK2 | |
| SCHEMBL1921882 | 0.82 | PDGFRB (0.43) | EGLN1MEN1KMT2APDGFRBPDGFRA | |
| SCHEMBL27957477 | 0.81 | MEN1 (0.45) | EGLN1MEN1KMT2AL3MBTL1SPHK2 | |
| SCHEMBL18865248 | 0.80 | MAOB (0.54) | MEN1KMT2AL3MBTL1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | claimed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | claimed |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024079708-A1 | A PROCESS FOR THE PREPARATION OF VADADUSTAT OR SALTS THEREOF | AMI LIFESCIENCES PRIVATE LIMITED (IN) | 2024-04-18 | — | — | WO | disclosed |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-116472266-A | Compounds as prolyl hydroxylase inhibitors and methods of making the same | 苏中药业集团股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| EP-4095127-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| US-8323671-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2327696-A1 | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (PR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2044005-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2010-10-20 | — | — | EP | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885VEGFA 76/4885FLT1 90/4885 |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885VEGFA 117/4885FLT1 55/4885 |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | DIMT1, DLAT, COASY | EGLN1 1247/4885VEGFA 747/4885FLT1 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.